These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8290015)

  • 21. [The use of recombinant erythropoietin with patients on programmed hemodialysis].
    Rozental' RL; Zezina LIu; Spudass AV
    Ter Arkh; 1991; 63(12):110-3. PubMed ID: 1803587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients.
    Lago M; Pérez-García R; García de Vinuesa MS; Anaya F; Valderrábano F
    Nephron; 1996; 72(4):723-4. PubMed ID: 8730458
    [No Abstract]   [Full Text] [Related]  

  • 23. Erythrocyte delta-aminolevulinic acid dehydratase activity in porphyria cutanea tarda.
    Goerz G; Jacobs A; Vizethum W
    Arch Dermatol Res; 1980; 268(1):109-12. PubMed ID: 7416794
    [No Abstract]   [Full Text] [Related]  

  • 24. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 25. [In vitro effects of zinc and lead on the activity of erythrocyte delta-aminolevulinic acid dehydratase (author's transl)].
    Tomokuni K
    Sangyo Igaku; 1978 Jul; 20(4):222-3. PubMed ID: 702915
    [No Abstract]   [Full Text] [Related]  

  • 26. Changes of enzyme activity levels in red blood cells in hemodialysis patients by recombinant human erythropoietin.
    Suzuki Y; Ogura Y; Otsubo O; Mimura N; Takaku F; Maeda T
    Nihon Jinzo Gakkai Shi; 1992 Sep; 34(9):1019-23. PubMed ID: 1479730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of recombinant human erythropoietin (rEPO) on angina pectoris in patients with chronic maintenance hemodialysis].
    Imamura Y; Hase H
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):403-8. PubMed ID: 1875559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The after effect of r-HuEPO in treating anemic hemodialysis patients].
    Chu JQ
    Zhonghua Hu Li Za Zhi; 1994 Feb; 29(2):78-9. PubMed ID: 7788758
    [No Abstract]   [Full Text] [Related]  

  • 29. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
    Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
    Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
    [No Abstract]   [Full Text] [Related]  

  • 30. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study.
    Bahlmann J; Schöter KH; Scigalla P; Gurland HJ; Hilfenhaus M; Koch KM; Muthny FA; Neumayer HH; Pommer W; Quelhorst E
    Contrib Nephrol; 1991; 88():90-106. PubMed ID: 2040200
    [No Abstract]   [Full Text] [Related]  

  • 31. Erythropoietin, oxidative metabolism and dialysis.
    Ionova D; Sepetlieva K; Tcachev K
    Nephron; 2000 Dec; 86(4):544. PubMed ID: 11124624
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of renal anemia with recombinant human erythropoietin.
    Schaefer RM; Hörl WH; Massry SG
    Am J Nephrol; 1989; 9(5):353-62. PubMed ID: 2679093
    [No Abstract]   [Full Text] [Related]  

  • 33. The use of human recombinant erythropoietin in children on chronic dialysis.
    Sallay P; Reusz G
    Acta Paediatr Hung; 1992; 32(4):333-45. PubMed ID: 1304191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of phenylhydrazine on delta-aminolevulinic acid dehydratase in red blood cells.
    Abdulla M; Svensson S
    Enzyme; 1978; 23(3):164-9. PubMed ID: 738253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.
    Grützmacher P; Tsobanelis T; Roth P; Werner E; Vlachojannis J; Kaltwasser J; Kurz P; Scheuermann EH; Schoeppe W
    Clin Nephrol; 1992; 38 Suppl 1():S92-7. PubMed ID: 1295714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis G and erythropoietin therapy in patients undergoing hemodialysis.
    Cengiz K; Günaydin M; Akpolat T; Pekbay A
    Nephron; 1998 Aug; 79(4):507. PubMed ID: 9689184
    [No Abstract]   [Full Text] [Related]  

  • 37. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 38. Resistance to recombinant human erythropoietin in a hemodialysis patient with lupus reactivation.
    Romero R; Novoa D; Perez-Freiria A; Arcocha V; Alonso R; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1995; 69(3):343-4. PubMed ID: 7753275
    [No Abstract]   [Full Text] [Related]  

  • 39. Reduced glutathione for the treatment of anemia during hemodialysis: a preliminary communication.
    Zachée P; Ferrant A; Daelemans R; Goossens W; Boogaerts MA; Lins RL
    Nephron; 1995; 71(3):343-9. PubMed ID: 8569984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.